Home Biosimilar Antibodies Apoptosis CD markers Belantamab (Anti-TNFRSF17 / BCMA / CD269)
For research use only. Not for use in humans.

Belantamab (Anti-TNFRSF17 / BCMA / CD269)

Synonyms: TNFRSF4， CD134

Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD.

Belantamab (Anti-TNFRSF17 / BCMA / CD269)

Click to purchase the isotype control of Belantamab (Anti-TNFRSF17 / BCMA / CD269)

Quality Control

Batch: A232801 Purity: 99% Protein concentration: 9.01mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD.

Product Details

CAS No. 2061894-48-0
Molecular Weight 145.5 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07790575 NOT_YET_RECRUITING Drug: AZD0120|Drug: Bendamustin Cytopenia Saurabh Dahiya 2026-09 PHASE1
NCT03549442 ACTIVE_NOT_RECRUITING Multiple Myeloma University of Pennsylvania 2018-05-09 PHASE1
NCT07274059 RECRUITING Drug: allogeneic umbilical cord blood-derived CAR-T targetin SLE - Systemic Lupus Erythematosus Chengdu Ucello Biotechnology Co., Ltd. 2025-03-26 EARLY_PHASE1
NCT07266337 NOT_YET_RECRUITING Drug: CD19/BCMA CAR T-cells SLE - Systemic Lupus Erythematosus Chengdu Ucello Biotechnology Co., Ltd. 2025-12-10 EARLY_PHASE1
NCT05828511 RECRUITING Drug: Linvoseltamab Multiple Myeloma Regeneron Pharmaceuticals 2023-12-19 PHASE1; PHASE2
NCT06669247 RECRUITING Drug: Linvoseltamab|Drug: REGN7945+Linvoseltamab Relapsed/Refractory Multiple Myeloma Regeneron Pharmaceuticals 2024-12-11 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-27)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.